ImmuPharma Historical Income Statement

IMM Stock

1.19 0.24 16.78%

Historical analysis of ImmuPharma PLC income statement accounts such as Selling General Administrative of 1.7 M or Other Operating Expenses of 5.1 M can show how well ImmuPharma PLC performed in making a profits. Evaluating ImmuPharma PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ImmuPharma PLC's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ImmuPharma PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ImmuPharma PLC is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About ImmuPharma Income Statement Analysis

ImmuPharma PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ImmuPharma PLC shareholders. The income statement also shows ImmuPharma investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ImmuPharma PLC Income Statement Chart

At present, ImmuPharma PLC's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 5.1 M, whereas Interest Expense is forecasted to decline to 1,887.

Selling General Administrative Other Operating Expenses Total Operating Expenses Research Development

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ImmuPharma PLC. It is also known as ImmuPharma PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from ImmuPharma PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ImmuPharma PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2021	2022	2023	2024 (projected)
Interest Expense	2.4M	1.5M	2.0K	1.9K
Depreciation And Amortization	114.1K	117.6K	37.6K	35.7K

Interest Expense Depreciation And Amortization

ImmuPharma PLC income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Research Development	Cost Of Revenue	Net Income From Continuing Ops	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.45	0.11	0.66	-0.72	-0.73	-0.72	0.66	-0.77	-0.33	-0.76	-0.56	0.7	0.44	0.6	-0.41	-0.68	0.24	-0.51	0.55	0.49	0.45
Interest Expense	0.45		-0.24	0.04	-0.2	-0.44	-0.43	0.04	-0.52	-0.97	-0.54	-0.14	0.14	0.13	0.01	-0.12	-0.57	0.42	-0.69	0.56	0.14	0.21
Selling General Administrative	0.11	-0.24		0.44	-0.36	-0.28	-0.28	0.44	-0.23	0.29	-0.23	-0.16	0.09	0.21	0.05	-0.7	0.09	-0.17	0.17	-0.09	0.17	0.04
Other Operating Expenses	0.66	0.04	0.44		-0.96	-0.87	-0.87	1.0	-0.86	0.04	-0.84	-0.72	0.5	0.41	0.86	-0.63	-0.67	0.23	0.05	0.09	0.09	0.06
Operating Income	-0.72	-0.2	-0.36	-0.96		0.96	0.96	-0.96	0.94	0.09	0.93	0.74	-0.55	-0.48	-0.84	0.6	0.79	-0.15	-0.03	-0.08	-0.2	-0.27
Ebit	-0.73	-0.44	-0.28	-0.87	0.96		1.0	-0.87	0.99	0.34	0.99	0.67	-0.55	-0.52	-0.75	0.55	0.89	-0.25	0.1	-0.17	-0.2	-0.28
Ebitda	-0.72	-0.43	-0.28	-0.87	0.96	1.0		-0.87	0.99	0.34	0.99	0.67	-0.55	-0.52	-0.75	0.55	0.89	-0.25	0.09	-0.16	-0.2	-0.27
Total Operating Expenses	0.66	0.04	0.44	1.0	-0.96	-0.87	-0.87		-0.86	0.04	-0.84	-0.72	0.5	0.41	0.86	-0.63	-0.67	0.23	0.05	0.09	0.09	0.06
Income Before Tax	-0.77	-0.52	-0.23	-0.86	0.94	0.99	0.99	-0.86		0.42	1.0	0.7	-0.51	-0.44	-0.74	0.58	0.88	-0.32	0.21	-0.26	-0.17	-0.25
Total Other Income Expense Net	-0.33	-0.97	0.29	0.04	0.09	0.34	0.34	0.04	0.42		0.45	0.08	-0.02	-0.03	0.07	0.11	0.47	-0.54	0.66	-0.54	0.05	-0.02
Net Income	-0.76	-0.54	-0.23	-0.84	0.93	0.99	0.99	-0.84	1.0	0.45		0.64	-0.5	-0.47	-0.7	0.56	0.9	-0.34	0.23	-0.29	-0.19	-0.26
Income Tax Expense	-0.56	-0.14	-0.16	-0.72	0.74	0.67	0.67	-0.72	0.7	0.08	0.64		-0.41	-0.09	-0.82	0.6	0.43	-0.05	-0.06	0.07	0.05	-0.07
Total Revenue	0.7	0.14	0.09	0.5	-0.55	-0.55	-0.55	0.5	-0.51	-0.02	-0.5	-0.41		0.81	0.53	-0.16	-0.51	-0.09	-0.02	0.03	0.43	0.39
Gross Profit	0.44	0.13	0.21	0.41	-0.48	-0.52	-0.52	0.41	-0.44	-0.03	-0.47	-0.09	0.81		0.28	-0.05	-0.55	-0.03	0.1	-0.04	0.39	0.35
Research Development	0.6	0.01	0.05	0.86	-0.84	-0.75	-0.75	0.86	-0.74	0.07	-0.7	-0.82	0.53	0.28		-0.39	-0.62	0.1	0.14	-0.08	0.03	0.03
Cost Of Revenue	-0.41	-0.12	-0.7	-0.63	0.6	0.55	0.55	-0.63	0.58	0.11	0.56	0.6	-0.16	-0.05	-0.39		0.14	-0.24	0.09	-0.1	0.13	0.11
Net Income From Continuing Ops	-0.68	-0.57	0.09	-0.67	0.79	0.89	0.89	-0.67	0.88	0.47	0.9	0.43	-0.51	-0.55	-0.62	0.14		-0.28	0.22	-0.28	-0.3	-0.38
Tax Provision	0.24	0.42	-0.17	0.23	-0.15	-0.25	-0.25	0.23	-0.32	-0.54	-0.34	-0.05	-0.09	-0.03	0.1	-0.24	-0.28		-0.54	0.61	-0.49	-0.49
Net Interest Income	-0.51	-0.69	0.17	0.05	-0.03	0.1	0.09	0.05	0.21	0.66	0.23	-0.06	-0.02	0.1	0.14	0.09	0.22	-0.54		-0.95	-0.27	-0.16
Interest Income	0.55	0.56	-0.09	0.09	-0.08	-0.17	-0.16	0.09	-0.26	-0.54	-0.29	0.07	0.03	-0.04	-0.08	-0.1	-0.28	0.61	-0.95		0.27	0.14
Reconciled Depreciation	0.49	0.14	0.17	0.09	-0.2	-0.2	-0.2	0.09	-0.17	0.05	-0.19	0.05	0.43	0.39	0.03	0.13	-0.3	-0.49	-0.27	0.27		0.84
Selling And Marketing Expenses	0.45	0.21	0.04	0.06	-0.27	-0.28	-0.27	0.06	-0.25	-0.02	-0.26	-0.07	0.39	0.35	0.03	0.11	-0.38	-0.49	-0.16	0.14	0.84

Click cells to compare fundamentals

ImmuPharma PLC Account Relationship Matchups

ImmuPharma PLC income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	90.3K	171.0K	114.1K	117.6K	37.6K	35.7K
Interest Expense	526.7K	1.7M	2.4M	1.5M	2.0K	1.9K
Selling General Administrative	1.8M	1.8M	1.0M	846.6K	1.0M	1.7M
Other Operating Expenses	6.4M	5.7M	5.3M	3.0M	3.1M	5.1M
Operating Income	(6.3M)	(5.6M)	(6.6M)	(3.0M)	(3.1M)	(3.2M)
Ebit	(6.7M)	(7.0M)	(8.8M)	(3.0M)	(3.1M)	(3.2M)
Ebitda	(6.7M)	(6.8M)	(8.7M)	(2.9M)	(3.0M)	(3.2M)
Total Operating Expenses	6.4M	5.7M	5.3M	3.0M	3.1M	5.1M
Income Before Tax	(6.7M)	(7.2M)	(8.9M)	(4.5M)	(3.4M)	(3.6M)
Total Other Income Expense Net	(462.7K)	(1.7M)	(2.4M)	(1.4M)	(355.9K)	(338.1K)
Net Income	(6.1M)	(6.9M)	(8.2M)	(3.8M)	(2.9M)	(3.1M)
Income Tax Expense	(620.8K)	(386.2K)	(766.8K)	(648.9K)	(497.1K)	(522.0K)
Gross Profit	77.9K	126.7K	118.4K	(117.6K)	(37.6K)	(35.7K)
Research Development	2.7M	2.4M	3.7M	2.0M	2.0M	3.0M
Net Income Applicable To Common Shares	(7.2M)	(6.1M)	(6.9M)	(8.2M)	(7.4M)	(7.0M)
Net Income From Continuing Ops	(6.1M)	(6.9M)	(8.2M)	(3.8M)	(2.9M)	(3.1M)
Tax Provision	(620.8K)	(386.2K)	(766.8K)	(648.9K)	(497.1K)	(522.0K)
Net Interest Income	1.7K	(1.7M)	(205.2K)	(1.4M)	1.0K	1.1K
Interest Income	5.7K	41.1K	651.0	28.6K	3.0K	2.9K
Reconciled Depreciation	88.0K	171.0K	114.1K	117.6K	37.6K	35.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in ImmuPharma Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ImmuPharma Historical Income Statement

About ImmuPharma Income Statement Analysis

ImmuPharma PLC Income Statement Chart

Other Operating Expenses

Total Operating Expenses

ImmuPharma PLC income statement Correlations

ImmuPharma PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ImmuPharma PLC income statement Accounts

Also Currently Popular

Other Information on Investing in ImmuPharma Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Income Before Tax	+ 0.99	Ebit
Net Income	+ 0.99	Ebit
Income Before Tax	+ 0.99	Ebitda

Total Other Income Expense Net	- 0.97	Interest Expense
Total Operating Expenses	- 0.96	Operating Income
Operating Income	- 0.96	Other Operating Expenses
Interest Income	- 0.95	Net Interest Income
Total Operating Expenses	- 0.87	Ebitda
Total Operating Expenses	- 0.87	Ebit